CAC1, 7255_clG, 7255cloneG, 7255_CACNA1S-01 cloneG
The cell line is not validated yet.
ISTEMi004-A
General
Cell Line |
|
| hPSCreg name | ISTEMi004-A |
| Cite as: | ISTEMi004-A |
| Alternative name(s) |
CAC1, 7255_clG, 7255cloneG, 7255_CACNA1S-01 cloneG
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 13th February 2025 |
| User feedback | |
Provider |
|
| Generator | Institut from Stem cell Therapy and Exploration of Monogenic diseases (ISTEM) |
| Distributors | |
| Derivation country | France |
External Databases |
|
| BioSamples | SAMEA117659039 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | French European/Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
| BioSamples | SAMEA117659042 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | MYOPHARM project |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | No |
| a for-profit corporation? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | COMITE DE PROTECTION DES PERSONNES SUD-OUEST ET OUTRE MER III |
| Approval number | ID 2611 n°19.01.07.64959 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | COMITE DE PROTECTION DES PERSONNES SUD-OUEST ET OUTRE MER III |
| Approval number | ID 2611 n°19.01.07.64959 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Vitronectin | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Other medium:
Base medium: StemMACS IPS-BREW XF
Main protein source: Serum concentration: % Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| SOX17 |
Yes |
| FOXA2 |
Yes |
Morphology
CAC1_7255clG_Endoderm_merge.tif
SOX17 in green; FOXA2 in red
In vitro spontaneous differentiation
| Marker | Expressed |
| T/Brachyury |
Yes |
| ACTA2/aSMA |
Yes |
Morphology
CAC1_7255clG_Mesoderm_merge.tif
ACTA2/aSMA in green; T/Brachyury in red
In vitro spontaneous differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| TUBB3/TUJ1 |
Yes |
Morphology
CAC1_7255clG_Ectoderm_merge.tif
TUBB3/TUJ1 in green; PAX6 in red
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.